leisure time -WSS

leisure time

author：knowledge 2025-09-30 01:14:08 - browse：956

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

focus

hotspot

WSS

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Elevance, private equity launch primary care company

Steward Health Care Massachusetts hospitals face fiscal disaster

CDC wastewater surveillance dashboard to track bird flu hotspots

EPA limits use of carcinogenic gas for sterilizing medical devices

Why scientists need input from humanists on sensitive research

entertainment

leisure time

hotspot

Sports medicine is finally prioritizing gender equality

Apple Watch's A

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Continuity nursing helped my family in our darkest PICU moments

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

How to save PrEP access — and even expand it

How many hemophilia patients actually want gene therapy?

BioMarin wins approval for gene therapy to treat hemophilia A

Making AI in medicine accessible to smaller, and rural hospitals

hotspot

Readout LOUD podcast: brain research, obesity drug sales, Novartis

FDA advisers back CAR

Male and female sex labels in research insufficient, scientists say

Pushing for an NIH office for post

H5N1 bird flu: what we're starting to learn about infection in cows

CDC wastewater surveillance dashboard to track bird flu hotspots

entertainment

focus

hotspot

explore